Oramed Pharmaceuticals (ORMP) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares.
View ORMP analyst ratings or view top-rated stocks.

3 brokers have issued 12 month price objectives for Oramed Pharmaceuticals' shares. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 372.6% from the stock's current price.
View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts.

Oramed Pharmaceuticals' stock was trading at $12.03 at the start of the year. Since then, ORMP stock has decreased by 66.6% and is now trading at $4.02.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ORMP earnings forecast.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its earnings results on Monday, March, 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $0.75 million. Oramed Pharmaceuticals had a negative trailing twelve-month return on equity of 19.46% and a negative net margin of 1,093.27%.

ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and BlueStar Israel Technology ETF (ITEQ) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (3.41%), Two Sigma Investments LP (1.26%), Two Sigma Advisers LP (1.11%), JPMorgan Chase & Co. (0.43%), XTX Topco Ltd (0.38%) and Susquehanna International Group Ltd. (0.28%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov.
View institutional ownership trends.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORMP stock can currently be purchased for approximately $4.02.

Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $160.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004.